NOV 17, 2016 07:00 AM PST

Using patient-derived iPSCs to model and treat inherited retinal degenerative blindness

Speakers
  • Stephen A. Wynn Associate Professor of Regenerative Ophthalmology, Director Steven W. Dezii Translational Vision Research Facility, Wynn Institute for Vision Research, Department of Ophthal
    Biography
      Dr. Tucker was born and raised in a small fishing village (population of less than 100) on the northern tip of Newfoundland, Canada. He attended Sir Wilfred Grenfell College in Corner Brook Newfoundland, where in 2001 as an undergraduate student he received his bachelor's degree in Psychology. In 2006 Dr. Tucker went on to complete his Ph.D. degree in neuroscience at Memorial University of Newfoundland's School of Medicine. He subsequently completed a 3-year postdoctoral fellowship at the Schepens Eye Research Institute, Harvard Medical School, where in 2009 under the mentorship of Dr. Michael J. Young he was promoted to the rank of faculty. In 2010 Dr. Tucker joined the Department at the University of Iowa where he is currently an Associate Professor of Ophthalmology and Visual Science. Dr. Tucker has a long-standing interest in the treatment of inherited retinal degenerative diseases such as retinitis pigmentosa (RP), Stargardt disease, Usher Syndrome, and age-related macular degeneration (AMD). His lab is focused on combining state-of-the-art patient-specific stem cell, gene augmentation/genome editing, and tissue engineering based technologies to develop treatments for inherited retinal degenerative blindness.

    Abstract:

    Inherited retinal degenerative disorders such as retinitis pigmentosa are characterized by death of the light sensing photoreceptive neurons of the outer retina. Like the rest of the CNS, the retina has little capacity for endogenous regeneration, and as a result, photoreceptor cell death causes debilitating irreversible blindness. Gene augmentation has the potential to prevent photoreceptor cell death, while cell replacement could actually repopulate the retina with new functioning photoreceptor cells and restore vision. In this talk I will show how we are using patient-specific iPSCs to evaluate disease pathophysiology, test novel gene-based therapeutics and develop autologous photoreceptor cell replacement for the treatment of retinal degenerative blindness.
     


    Show Resources
    You May Also Like
    MAY 02, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 02, 2018 08:00 AM PDT
    Immunohistochemistry protocols, which utilize antibodies to visualize proteins in tissue sections, have many steps that need optimized to prevent non-specific background effects, artifacts, o...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    OCT 19, 2017 08:00 AM PDT
    C.E. CREDITS
    OCT 19, 2017 08:00 AM PDT
    DATE: October 19, 2017TIME: 08:00am PDT, 11:00am EDT Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than...
    SEP 06, 2017 09:00 AM PDT
    C.E. CREDITS
    SEP 06, 2017 09:00 AM PDT
    DATE: September 6, 2017TIME: 9:00AM PST, 12:00PM ET The era of using extracellular vesicles (EVs) and exosomes for regenerative medicine applications in the clinic is here. We...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    Loading Comments...